PT  - JOURNAL ARTICLE
AU  - Schimmoller, Brian J.
AU  - Trovão, Nídia S.
AU  - Isbell, Molly
AU  - Goel, Chirag
AU  - Heck, Benjamin F.
AU  - Archer, Tenley C.
AU  - Cardinal, Klint D.
AU  - Naik, Neil B.
AU  - Dutta, Som
AU  - Daniel, Ahleah Rohr
AU  - Beheshti, Afshin
TI  - Covid-19 Exposure Assessment Tool (CEAT): Easy-to-use tool to quantify exposure based on airflow, group behavior, and infection prevalence in the community
AID  - 10.1101/2022.03.02.22271806
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.02.22271806
4099  - http://medrxiv.org/content/early/2022/03/05/2022.03.02.22271806.short
4100  - http://medrxiv.org/content/early/2022/03/05/2022.03.02.22271806.full
AB  - The COVID-19 Exposure Assessment Tool (CEAT) allows users to compare respiratory relative risk to SARS-CoV-2 for various scenarios, providing understanding of how combinations of protective measures affect exposure, dose, and risk. CEAT incorporates mechanistic, stochastic and epidemiological factors including the: 1) emission rate of virus, 2) viral aerosol degradation and removal, 3) duration of activity/exposure, 4) inhalation rates, 5) ventilation rates (indoors/outdoors), 6) volume of indoor space, 7) filtration, 8) mask use and effectiveness, 9) distance between people, 10) group size, 11) current infection rates by variant, 12) prevalence of infection and immunity in the community, 13) vaccination rates of the community, and 14) implementation of COVID-19 testing procedures. Demonstration of CEAT, from published studies of COVID-19 transmission events, shows the model accurately predicts transmission. We also show how health and safety professionals at NASA Ames Research Center used CEAT to manage potential risks posed by SARS-CoV-2 exposures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementB.S. and M.I. developed the CEAT concept, method, model, code and user interface, conducted literature reviews, and prepared this manuscript using solely Signature Science, LLC provided Internal Research and Development (IR&D) funding. S.D. was supported by the DOE Office of Science through the National Virtual Biotechnology Laboratory (NVBL), a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. A.B. is supported by supplemental funds for COVID-19 research from Translational Research Institute for Space Health through NASA Cooperative Agreement NNX16AO69A (T-0404) and further funding was provided by KBR, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the author.